TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications
Cancers · 03.09.2024 · 16 (17) · 3069
DOI: 10.3390/cancers16173069 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 03.09.2024. Verfasst von Chuqi Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy & Pharmaceutical Sciences, National University of Singapore, Singapore 117559, Singapore. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Paris-NUS Call.
Abstract (Originalsprache)
Mutation in p53 is the most frequent event in cancer development and a leading cause of cancer therapy resistance due to evasion of the apoptosis cascade. Beyond chemotherapies and radiation therapies, growing evidence indicates that p53-mutant tumors are resistant to a broad range of immune-based therapies, such as immune checkpoint inhibitors, chimeric antigen receptor (CAR) T, and hematopoietic stem cell transplantation (HSCT). This highlights the role of p53 mutations in driving immune evasion of tumor cells. In this review, we first summarize recent studies revealing mechanisms by which p53-mutant tumors evade immune surveillance from T cells, natural killer (NK) cells, and macrophages. We then review how these mutant tumor cells reshape the tumor microenvironment (TME), modulating bystander cells such as macrophages, neutrophils, and regulatory T (Treg) cells to foster immunosuppression. Additionally, we review clinical observations indicative of immune evasion associated with p53 loss or mutations. Finally, we discuss therapeutic strategies to enhance immune response in p53 wild-type (WT) or mutant tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy & Pharmaceutical Sciences, National University of Singapore, Singapore 117559, Singapore.
- Duke-NUS Medical School, Singapore 169857, Singapore.
ORCID-Profile: Chuqi Wang, Shruti Bhatt
Förderung
- Paris-NUS Call
Zitieren
APA
Wang, C., Tan, J. Y. M., Chitkara, N., & Bhatt, S. (2024). TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications. Cancers, 16(17), 3069. https://doi.org/10.3390/cancers16173069
Vancouver
Wang C, Tan JYM, Chitkara N, Bhatt S. TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications. Cancers. 2024;16(17):3069. doi:10.3390/cancers16173069
BibTeX
@article{Wang2024,
author = {Wang, Chuqi and Tan, Jordan Yong Ming and Chitkara, Nishtha and Bhatt, Shruti},
title = {TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications},
journal = {Cancers},
year = {2024},
volume = {16},
number = {17},
pages = {3069},
doi = {10.3390/cancers16173069}
}
EUVIMED